PMID- 35371097 OWN - NLM STAT- MEDLINE DCOM- 20220408 LR - 20220601 IS - 1664-3224 (Electronic) IS - 1664-3224 (Linking) VI - 13 DP - 2022 TI - Serum IgE Levels Are Associated With the Prognosis of Minimal Change Disease. PG - 840857 LID - 10.3389/fimmu.2022.840857 [doi] LID - 840857 AB - BACKGROUND: Previous reports showed that some patients with minimal change disease (MCD) had high serum immunoglobulin E (IgE) levels. This study aimed to explore the proportion of MCD patients with high serum IgE levels and evaluate the correlation between serum IgE levels and MCD remission and relapse. METHODS: This study enrolled 222 new-onset patients with renal biopsy-confirmed MCD from October 2012 to October 2019 at the First Affiliated Hospital of Zhejiang University in Hangzhou, China. Patients' demographics and clinical parameters were analyzed. RESULTS: The results indicated that 70.3% of 222 MCD patients had high serum IgE levels (IgE > 100.0 IU/mL). Moreover, 134 patients were treated with glucocorticoids alone and divided into the low- and high-IgE groups, according to the median serum IgE level (523.5 IU/mL). The mean time to complete remission of the low- and high-IgE groups was 29.0 +/- 2.2 and 45.7 +/- 4.2 days, respectively (log-rank test; P = 0.002). The mean time to total remission was 19.1 +/- 1.4 and 31.6 +/- 3.2 days of the low- and high-IgE groups, respectively (log-rank test; P < 0.001). The mean time to first relapse in the low- and high-IgE groups was 701.2 +/- 65.0 and 425.0 +/- 52.6 days, respectively (log-rank test; P = 0.002). Serum IgE >/= 523.5 IU/mL was an independent correlation factor affecting the patients' remission and relapse. CONCLUSION: Serum IgE level was an independent correlation factor for MCD remission and relapse. MCD patients with high serum IgE levels were prone to delayed remissions and early relapses. CI - Copyright (c) 2022 Li, Wang, Li, Chen, Zhang and Chen. FAU - Li, Heng AU - Li H AD - Kidney Disease Center, First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China. AD - Key Laboratory of Kidney Disease Prevention and Control Technology, Hangzhou, China. AD - National Key Clinical Department of Kidney Diseases, Hangzhou, China. AD - Institute of Nephrology, Zhejiang University, Hangzhou, China. AD - Zhejiang Clinical Research Center of Kidney and Urinary System Disease, Hangzhou, China. FAU - Wang, Lefeng AU - Wang L AD - Kidney Disease Center, First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China. AD - Key Laboratory of Kidney Disease Prevention and Control Technology, Hangzhou, China. AD - National Key Clinical Department of Kidney Diseases, Hangzhou, China. AD - Institute of Nephrology, Zhejiang University, Hangzhou, China. AD - Zhejiang Clinical Research Center of Kidney and Urinary System Disease, Hangzhou, China. FAU - Li, Xiayu AU - Li X AD - Kidney Disease Center, First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China. AD - Key Laboratory of Kidney Disease Prevention and Control Technology, Hangzhou, China. AD - National Key Clinical Department of Kidney Diseases, Hangzhou, China. AD - Institute of Nephrology, Zhejiang University, Hangzhou, China. AD - Zhejiang Clinical Research Center of Kidney and Urinary System Disease, Hangzhou, China. FAU - Chen, Wenqing AU - Chen W AD - Kidney Disease Center, First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China. AD - Key Laboratory of Kidney Disease Prevention and Control Technology, Hangzhou, China. AD - National Key Clinical Department of Kidney Diseases, Hangzhou, China. AD - Institute of Nephrology, Zhejiang University, Hangzhou, China. AD - Zhejiang Clinical Research Center of Kidney and Urinary System Disease, Hangzhou, China. FAU - Zhang, Ying AU - Zhang Y AD - Kidney Disease Center, First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China. AD - Key Laboratory of Kidney Disease Prevention and Control Technology, Hangzhou, China. AD - National Key Clinical Department of Kidney Diseases, Hangzhou, China. AD - Institute of Nephrology, Zhejiang University, Hangzhou, China. AD - Zhejiang Clinical Research Center of Kidney and Urinary System Disease, Hangzhou, China. FAU - Chen, Jianghua AU - Chen J AD - Kidney Disease Center, First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China. AD - Key Laboratory of Kidney Disease Prevention and Control Technology, Hangzhou, China. AD - National Key Clinical Department of Kidney Diseases, Hangzhou, China. AD - Institute of Nephrology, Zhejiang University, Hangzhou, China. AD - Zhejiang Clinical Research Center of Kidney and Urinary System Disease, Hangzhou, China. LA - eng PT - Journal Article DEP - 20220317 PL - Switzerland TA - Front Immunol JT - Frontiers in immunology JID - 101560960 RN - 37341-29-0 (Immunoglobulin E) SB - IM MH - Humans MH - Immunoglobulin E MH - *Nephrosis, Lipoid/complications/diagnosis/drug therapy MH - Prognosis MH - Recurrence MH - Remission Induction PMC - PMC8968917 OTO - NOTNLM OT - minimal change disease OT - relapse OT - remission OT - risk factor OT - serum IgE level COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2022/04/05 06:00 MHDA- 2022/04/09 06:00 PMCR- 2022/01/01 CRDT- 2022/04/04 05:29 PHST- 2021/12/21 00:00 [received] PHST- 2022/02/23 00:00 [accepted] PHST- 2022/04/04 05:29 [entrez] PHST- 2022/04/05 06:00 [pubmed] PHST- 2022/04/09 06:00 [medline] PHST- 2022/01/01 00:00 [pmc-release] AID - 10.3389/fimmu.2022.840857 [doi] PST - epublish SO - Front Immunol. 2022 Mar 17;13:840857. doi: 10.3389/fimmu.2022.840857. eCollection 2022.